Ixazomib (Ixazomib)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents

Included in the formulation
  • Ninlaro®
    capsules inwards 
    Millennium Pharmaceuticals Incorporated     USA
    • АТХ:

    L.01.X.X.50   Ixazomib

    Pharmacodynamics:

    Reversibly inhibits beta-5 subunit 20S proteasome, thereby inhibiting the chymotrypsin activity of melanoma cells. Causes apoptosis of multiple myeloma cell lines.

    Pharmacokinetics:

    After oral administration, up to 58% is absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is achieved through 1 hour. The connection with plasma proteins is 99%.

    Metabolism in the liver.

    The half-life period is 9.5 days. Elimination by the kidneys (68%) and with feces (22%). Less than 3.5% - unchanged.

    Indications:

    It is used in combination therapy of multiple myeloma with dexamethasone and lenalidomide.

    ICD-10

    II.C81-C96.C90.0   Multiple myeloma

    Contraindications:

    Age to 18 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Thrombocytopenia, severe renal and hepatic insufficiency, hypersensitivity.

    Pregnancy and lactation:Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.


    Dosing and Administration:

    Inside, 4 mg once a week, at 1, 8 and 15 days with a 28-day course of treatment. Lenalidomide and dexamethasone taken simultaneously, 25 mg and 40 mg, respectively.

    The highest daily dose: 4 mg.

    The highest single dose: 4 mg.

    Side effects:

    Central and peripheral nervous system: peripheral neuropathy.

    Hemopoietic system: thrombocytopenia, neutropenia.

    Digestive system: nausea, vomiting, constipation, diarrhea.

    Musculoskeletal system: back pain.

    Dermatological reactions: a rash.

    Sense organs: a vision disorder, cataract.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Rifampicin, carbamazepine, phenytoin, preparations of St. John's wort penetrate reduce the concentration of Ixazomib.

    Special instructions:

    Persons of reproductive age during the treatment period and within 6 months after the end of it are recommended to use reliable methods of contraception.

    During the reception of Ixazomib and within 3 months after treatment, vaccination is not recommended.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up